Primary non-Hodgkin's lymphomas of the paranasal sinuses and nasal cavity. A report of 18 cases with stage IE disease.

During a 26-year period (1961-1987), a total of 18 patients with primary non-Hodgkin's lymphoma (NHL) of the paranasal sinuses and nasal cavity received radiation therapy at (University of California at Los Angeles) UCLA Medical Center. At the time of diagnosis and using the available diagnostic methods, none of these patients had clinically detectable disease beyond the paranasal sinuses. All 18 patients were staged IE by the Ann-Arbor system. When the patients were staged according to the AJC staging system from epithelial tumors, half presented with advanced T3-4 disease. Diffuse histiocytic lymphoma was the most common histology (eight cases) and maxillary sinus, the most common site of origin (11 cases). All nine T1-2 tumors received radiation therapy alone, while radiation and chemotherapy was used in seven of nine advanced T3-4 staged tumors. The mean follow-up was 71 months. At last follow-up, eight of nine T1-2 patients were rendered disease-free. In contrast, only four of nine T3-4 patients had long-term disease-free survival. Seventy-five percent of the failure occurred within 2 years. Radiation therapy alone achieves high local control in small tumors (T1-2), while large tumors (T3-4) require aggressive combined treatment, i.e., radiation and chemotherapy.     

In situ forces in the anterior cruciate ligament and its bundles in response to anterior tibial loads

The anterior cruciate ligament has a complex fiber anatomy and is not considered to be a uniform structure. Current anterior cruciate ligament reconstructions succeed in stabilizing the knee, but they neither fully restore normal knee kinematics nor reproduce normal ligament, function. To improve the outcome of the reconstruction, it may be necessary to reproduce the complex function of the intact anterior cruciate ligament in the replacement graft. We examined the in situ forces in nine human anterior cruciate ligaments as well as the force distribution between the anteromedial and posterolateral bundles of the ligament in response to applied anterioi tibial loads ranging from 22 to 110 N at knee flexion angles of 0–90°. The analysis was performed using a robotic manipulator in conjunction with a universal force-moment sensor. The in situ forces were determined with no device attached to the ligament, while the knee was permitted to move freely in response to the applied loads. We found that the in situ forces in the anterior cruciate ligament ranged from 12.8 ± 7.3 N under 22 N of anterior tibial load applied at 90° of knee flexion to 110.6 ± 14.8 N under 110 N of applied load at 15° of flexion. The magnitude of the in situ force in the posterolateral bundle was larger than that in the anteromedial bundle at knee flexion angles between 0 and 45°, reaching a maximum of 75.2 ± 18.3 N at 15° of knee flexion under an anterior tibial load of 110 N. The magnitude of the in situ force in the posterolateral bundle was significantly affected by knee flexion angle and anterior tibial load in a fashion remarkably similar to that seen in the anterior cruciate ligament. The magnitude of the in situ force in the anteromedial bundle, in contrast, remained relatively constant, not changing with flexion angle. Significant differences in the direction of the in situ force between the anteromedial bundle and the posterolateral bundle were found only at flexion angles of 0 and 60° and only under applied anterior tibial loads greater than 66 N. We have demonstrated the nonuniformity of the anterior cruciate ligament under unconstrained anterior tibial loads. Our data further suggest that in order for the anterior cruciate ligament replacement graft to reproduce the in situ forces of the normal anterior cruciate ligament, reconstruction techniques should take into account the role of the posterolateral bundle in addition to that of the anteromedial bundle.     

血康口服液与他莫昔芬联合治疗免疫性血小板减少性紫癜疗效观察

联合应用血康口服液和他莫昔芬治疗成人免疫性血小板减少性紫癜(ITP)20例。疗程超过2月。15例患者的血小板(BPC)计数明显上升,有效率为75％(15/20),对于激素治疗无效者,仍有良效。对月经过多者和不适合应用激素者尤为适应。两药合用无明显副作用。治疗起效时间较快,平均13天。疗效持续时间较长,长者已达一年以上。     

我省流通领域阿莫西林制剂质量现状

目的:了解流通领域中阿莫西林制剂的质量状况。方法:在全省各市县的部分医药经营企业,抽取阿莫西林胶囊及干糖浆共54批样品,按国家药品标准进行全检后,对其检验结果进行统计分析。结果:不合格的项目有含量、胶囊剂溶出度、干糖浆粒度。该药物制剂的标示百分含量普遍偏低。结论:影响该产品质量的主要项目是含量和溶出度,含量偏低的主要原因是厂家的低限投料,应予以充分重视。     

利用生物电阻抗测量人体脂肪的研究

本文根据瘦体组织电传导远比脂肪组织强的原理，研制了人体脂肪分析仪（ＢＦＡ），采用４个电极，引出无痛信号（８００μＡ、５０ｋＨｚ）进入人体，测试电阻抗（Ｚ），编入计算机软件，运算人体脂肪量。选择３０名１８～２０岁男性青年进行测量条件试验，得出食后半小时，上午、下午检测均可，喝少量水（少于５００ｍｌ）对测量无明显影响（Ｐ＞０．０５）。另选５２名受试者（男９，女４３）年龄１９～６５岁，对用ＢＦＡ测量的Ｚ、体脂百分比（％ＢＦ）和用美国ＢＣ一３００人体成分分析仪测量的电阻（Ｒ）、％ＢＦ进行了相关分析，ｒ值分别为０．９９５（Ｓ（ｙ．ｘ））＝７．９７，Ｐ＜０．０１）和０．９９６（Ｓ（ｙ．ｘ））＝０．６１，Ｐ＜０．０１）。最后，用ＢＦＡ对７９名健康人（男２２，女５７）、年龄３９．０±１１．８岁、身高１６３±７．０ｃｍ、体重６３．１±１０．２ｋｇ测量体脂，男性体脂２２．５±９．２％，女性体脂３４．７±７．２％，用体脂判断肥胖比用体重判断肥胖发生率高，特别是女人、中老年人更明显。     

流产鼠Caspase-3与laminin B和PAI-1的表达及对妊娠结局的影响

目的:研究阻断CD86协同刺激分子对自然流产模型孕鼠母胎界面Caspase-3、laminin B和PAI-1的表达及对妊娠结局的影响。方法:实验组于妊娠第4.5天腹腔注射大鼠抗小鼠CD86单抗,实验对照组注射大鼠同型IgG2b,正常妊娠组不作任何处理。于妊娠第13.5天计算胚胎吸收率,用免疫组化测定Caspase-3、laminin B和PAI-1的表达,并进行图像分析、检测免疫组化染色灰度值(A)。结果:①实验组的胚胎吸收率显著低于实验对照组(P<0.05);②实验组中Caspase-3蛋白灰度值明显高于实验对照组(P<0.05),实验组中laminin B和PAI-1蛋白灰度值均明显低于实验对照组(P<0.05)。结论:妊娠早期阻断CD86协同刺激分子可使母胎界面中的Caspase-3、laminin B和PAI-1分别通过各自不同的途径发挥免疫耐受作用并且使自然流产模型孕鼠的胚胎吸收率降低至正常妊娠水平。     

心理疏导对孕妇羊水穿刺预约率的影响

为提高出生人口素质,我院自2004年3月开始对孕妇开展产前筛查.通过对孕15周～19周孕妇的血清标志物检查,结合孕妇的年龄、体重和末次月经进行唐氏综合征(DS)、18-三体综合征(爱德华综合征)和神经管畸形(NTD)的风险率估计,筛选出来的DS和18-三体综合征高风险者再进行羊水染色体分析,NTD高风险者用B超进一步确诊,对这3种先天畸形进行产前诊断,以降低先天缺陷儿的出生率.但高风险孕妇普遍存在心理顾虑,在一定程度上影响了进一步产前诊断--羊水穿刺配合率,需要及时进行心理疏导.     

微电流与低浓度氯对水中脊髓灰质炎I型病毒的协同灭活效应

目的　观察微电流 (low amperage direct current,LDC)与游离氯 (free chlorine,FC)对水中脊髓灰质炎 I型病毒 (PV1 )的协同灭活效果 .方法　用微电流 0 .4～ 1 .2 m A·cm-2 协同氯 0 .2～ 0 .3 mg· L-1 处理污染 PV1水样 ,比较作用前后灭活率 K值评价灭活效果 ,用 Berenbaum方法判断微电流与氯灭活病毒有无协同效应 ,用蚀斑形成试验 (PFUA)和病毒细胞酶联免疫试验 (VELCIA)检测感染性和抗原性变化 .结果　实验观察到微电流达到 0 .4 m A· cm-2 对水中PV1有弱灭活作用 ,电流密度达到 1 .2 m A· cm-2 与 0 .2mg· L-1氯有协同灭活效应 ,微电流 1 .2 m A· cm-2与氯 0 .3mg· L-1协同消毒 30 min,水中病毒减少 4.0 8个对数级 ,而单独用氯仅减少 1 .93个对数级 ;协同作用后病毒感染性灭活增强 ,而抗原性灭活不明显 .结论　微电流协同氯可提高低浓度氯灭活水中病毒的效果